
About Clinitech Laboratory
Clinitech Laboratory is a publicly listed company based in Mumbai (India) founded in 1990. Pathology lab services are operated through a chain in India. Its chief executive, as recorded, is Jagdish Nayak. Its Indian entity Clinitech Laboratory Limited reported revenue of ₹9.68 Cr. Its focus areas include Clinical Laboratory Chains and Pathology. Similar companies include Dr Lal PathLabs, Redcliffe Labs and Sterling Accuris Diagnostics; 3 of its 3 listed similar companies have raised funding.
Company details
Clinitech Laboratory was founded in 1990 and functions as a chain of pathology labs based in Mumbai, India. Diagnostic services in pathology are delivered across multiple locations. Operations focus on medical testing and analysis for healthcare needs. Leadership is provided by CEO Jagdish Nayak. The company serves the healthcare sector within the Indian market.
- Headquarters Mumbai, India
- Stage Public
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website clinitechlab.com
- Social X Facebook
- Legal Name Clinitech Laboratory Limited
- Date of Incorporation 19 Mar, 2010
- Jurisdiction Navi Mumbai, Maharashtra, India
- Market Cap₹7.79 Cr
CTLLAB · BSE
- Share Price₹32.05
-6.15% today
- Revenue₹9.49 Cr
FY 2025-26 · +15.3% YoY
- EBITDA₹1.00 Cr
Margin 10.5%
- Net Profit₹0.43 Cr
FY 2025-26 · +48.3% YoY
- P/E (TTM)17.7x
P/B 0.8x
- ROE4.5%
ROCE 6.9%
- Debt / Equity0.03
Interest cover 14.3x
Associated legal entities of Clinitech Laboratory
Clinitech Laboratory is associated with 2 registered companies on The Company Check; the primary company is Clinitech Laboratory Limited, a listed company. Each company page carries the filings, financials, charges and directors of that entity.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2026) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Clinitech Laboratory Limited Listed CIN L85195MH2010PLC201078 | Active | 19 Mar 2010 | Navi Mumbai, Maharashtra | ₹9.7 Cr | 13 | 8 | View details |
| Ctl Wellnz Llp CIN AAV-4037 | Strike Off | 09 Jan 2021 | Navi Mumbai, Maharashtra | 3 | View details |
Board of directors of Clinitech Laboratory Limited (Clinitech Laboratory)
Clinitech Laboratory Limited is the primary company behind Clinitech Laboratory. The boards of the 2 registered companies of Clinitech Laboratory currently have 7 directors; the longest-serving is Jyoti Jagdish Nayak, appointed in 2010. 6 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Jyoti Jagdish Nayak DIN 02945625 | Whole-time director | 19 Mar 2010 | 16 yrs 8 mo | Clinitech Laboratory Limited |
| Jagdish Umakant Nayak DIN 00646672 | Designated Partner | 09 Jan 2021 | 5 yrs 10 mo | Ctl Wellnz Llp, Clinitech Laboratory Limited |
| Ashutosh Jagdish Nayak DIN 07553633 | Designated Partner | 09 Jan 2021 | 5 yrs 10 mo | Ctl Wellnz Llp, Clinitech Laboratory Limited |
| Kripananda Chidambaram DIN 03030134 | Partner | 09 Jan 2021 | 5 yrs 10 mo | Ctl Wellnz Llp |
| Balu Laxman Kumbharkar DIN 10180137 | Director | 19 Jun 2023 | 3 yrs 5 mo | Clinitech Laboratory Limited |
| Ravikant Moreshwar Mhatre DIN 06362676 | Director | 19 Jun 2023 | 3 yrs 5 mo | Clinitech Laboratory Limited |
| Smita Arjun Patil DIN 10147488 | Director | 19 Jun 2023 | 3 yrs 5 mo | Clinitech Laboratory Limited |
People of Clinitech Laboratory
1 people are tracked at Clinitech Laboratory (1 in leadership).
| Name | Role | Group |
|---|---|---|
| CEO | Leadership |
Complete people profiles for Clinitech Laboratory
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Clinitech Laboratory
Clinitech Laboratory is a publicly listed company on the BSE with ticker symbol CTLLAB in India, operating in the Healthcare sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date01 Aug 2024
- Listed onBSE: 544220
- Listed entityClinitech Laboratory Limited
- Exchange sectorHealthcare
Financials of Clinitech Laboratory
Exchange-reported figures of Clinitech Laboratory Limited, the listed company behind Clinitech Laboratory (BSE: CTLLAB).
Financial Highlights
FY 2025-26 · ConsolidatedRevenue vs Net Profit ₹ Cr
Margin trends
Financial summary ₹ Cr
| Metrics | FY 2025-26 | FY 2024-25 |
|---|---|---|
| Income statement | ||
| Revenue | 9.49 | 8.23 |
| Revenue growth | +15.3% | - |
| EBITDA | 1.00 | 0.82 |
| EBITDA margin | +10.5% | +10.0% |
| Profit before tax | 0.61 | 0.54 |
| Net profit | 0.43 | 0.29 |
| Net profit margin | +4.5% | +3.5% |
| EPS (₹) | 1.83 | 1.73 |
| Balance sheet | ||
| Total assets | 10.04 | 9.03 |
| Net worth | 9.25 | 8.83 |
| Total debt | 0.54 | 0.00 |
| Cash & bank | 2.11 | 3.07 |
| Net working capital | 6.23 | 5.65 |
| Cash flow | ||
| Cash from operations | (0.79) | (0.88) |
| Cash from investing | (0.68) | (0.73) |
| Cash from financing | 0.51 | 3.98 |
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|---|
| Income statement | ||||||
| Revenue | 9.48 | 8.23 | 6.40 | 6.35 | 6.38 | 4.55 |
| Revenue growth | +15.2% | +28.6% | +0.8% | -0.5% | +40.2% | - |
| EBITDA | 1.00 | 0.82 | 1.00 | 1.36 | 1.06 | 0.83 |
| EBITDA margin | +10.6% | +10.0% | +15.6% | +21.4% | +16.6% | +18.2% |
| Profit before tax | 0.61 | 0.54 | 0.51 | 0.86 | 0.69 | 0.54 |
| Net profit | 0.43 | 0.29 | 0.37 | 0.61 | 0.50 | 0.37 |
| Net profit margin | +4.5% | +3.5% | +5.8% | +9.6% | +7.8% | +8.1% |
| EPS (₹) | 1.85 | 1.73 | 2.21 | 4.09 | 3.42 | 6.04 |
| Balance sheet | ||||||
| Total assets | 9.86 | 9.03 | 4.61 | 5.02 | 2.85 | 2.02 |
| Net worth | 9.25 | 8.83 | 3.55 | 2.38 | 1.85 | 1.39 |
| Total debt | 0.36 | 0.00 | 0.87 | 1.03 | 0.89 | 0.54 |
| Cash & bank | 2.06 | 3.07 | 0.70 | 0.78 | 0.10 | 0.32 |
| Net working capital | 6.31 | 5.65 | 1.70 | 0.95 | 0.55 | 0.92 |
| Cash flow | ||||||
| Cash from operations | (0.90) | (0.88) | (1.28) | 1.25 | 0.96 | 0.38 |
| Cash from investing | (0.44) | (0.73) | 0.75 | (0.65) | (1.47) | 0.54 |
| Cash from financing | 0.33 | 3.98 | 0.45 | 0.09 | 0.29 | (0.88) |
Financial Statements
| Particulars | FY 2025-26 | FY 2024-25 |
|---|---|---|
| Revenue | 9.49 | 8.23 |
| Revenue growth | +15.3% | - |
| Other income | 0.19 | 0.23 |
| Total expenses | 8.49 | 7.41 |
| Employee cost | 2.60 | 2.38 |
| EBITDA | 1.00 | 0.82 |
| EBITDA margin | +10.5% | +10.0% |
| Depreciation | 0.51 | 0.45 |
| Interest | 0.07 | 0.06 |
| Profit before tax | 0.61 | 0.54 |
| Tax | 0.18 | 0.16 |
| Net profit | 0.43 | 0.29 |
| Net profit margin | +4.5% | +3.5% |
| EPS (₹) | 1.83 | 1.73 |
| Particulars | FY 2025-26 | FY 2024-25 |
|---|---|---|
| Equity & liabilities | ||
| Share capital | 2.28 | 2.28 |
| Reserves & surplus | 6.97 | 6.55 |
| Shareholders' funds (net worth) | 9.25 | 8.83 |
| Minority interest | 0.00 | 0.00 |
| Secured loans | 0.54 | 0.00 |
| Unsecured loans | 0.00 | 0.00 |
| Total debt | 0.54 | 0.00 |
| Total liabilities | 10.04 | 9.03 |
| Assets | ||
| Gross block | 5.90 | 5.33 |
| Net block | 2.18 | 2.12 |
| Capital work in progress | 1.25 | 1.01 |
| Investments | 0.07 | 0.07 |
| Inventories | 0.73 | 0.53 |
| Sundry debtors | 1.85 | 1.54 |
| Cash & bank balances | 2.11 | 3.07 |
| Loans & advances | 2.68 | 2.32 |
| Total current assets | 7.37 | 7.46 |
| Total current liabilities | 1.14 | 1.81 |
| Net working capital | 6.23 | 5.65 |
| Total assets | 10.04 | 9.03 |
| Particulars | FY 2025-26 | FY 2024-25 |
|---|---|---|
| Opening cash | 3.07 | 0.70 |
| Net cash from operating activities | (0.79) | (0.88) |
| Net cash from investing activities | (0.68) | (0.73) |
| Net cash from financing activities | 0.51 | 3.98 |
| Net change in cash | (0.96) | 2.37 |
| Closing cash | 2.11 | 3.07 |
| Particulars | FY 2025-26 | FY 2024-25 |
|---|---|---|
| Growth | ||
| Sales growth | +15.3% | - |
| EBITDA growth | +22.0% | - |
| PBT growth | +13.0% | +9997.0% |
| Net income growth | +48.3% | - |
| Profitability & leverage | ||
| Net income margin | +4.5% | +4.6% |
| Return on capital employed | +6.9% | +6.0% |
| Return on net worth | +4.5% | +3.4% |
| Debt / equity | 0.03 | 0.00 |
| Long-term debt / equity | 0.03 | 0.00 |
| Interest cover | 14.29 | 16.22 |
| Efficiency & per share | ||
| Fixed asset turnover | 1.69 | 1.54 |
| Inventory turnover | 15.06 | 15.53 |
| Debtors turnover | 5.60 | 5.34 |
| EPS (₹) | 1.83 | 1.73 |
| Dividend per share (₹) | 0.00 | 0.00 |
| Book value per share (₹) | 40.52 | 38.69 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|---|
| Revenue | 9.48 | 8.23 | 6.40 | 6.35 | 6.38 | 4.55 |
| Revenue growth | +15.2% | +28.6% | +0.8% | -0.5% | +40.2% | - |
| Other income | 0.19 | 0.23 | 0.04 | 0.02 | 0.07 | 0.04 |
| Total expenses | 8.48 | 7.41 | 5.40 | 4.99 | 5.32 | 3.72 |
| Employee cost | 2.60 | 2.38 | 1.92 | 1.55 | 1.38 | 0.92 |
| EBITDA | 1.00 | 0.82 | 1.00 | 1.36 | 1.06 | 0.83 |
| EBITDA margin | +10.6% | +10.0% | +15.6% | +21.4% | +16.6% | +18.2% |
| Depreciation | 0.51 | 0.45 | 0.44 | 0.45 | 0.38 | 0.25 |
| Interest | 0.07 | 0.06 | 0.09 | 0.07 | 0.06 | 0.08 |
| Profit before tax | 0.61 | 0.54 | 0.51 | 0.86 | 0.69 | 0.54 |
| Tax | 0.18 | 0.16 | 0.13 | 0.25 | 0.19 | 0.14 |
| Net profit | 0.43 | 0.29 | 0.37 | 0.61 | 0.50 | 0.37 |
| Net profit margin | +4.5% | +3.5% | +5.8% | +9.6% | +7.8% | +8.1% |
| EPS (₹) | 1.85 | 1.73 | 2.21 | 4.09 | 3.42 | 6.04 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|---|
| Equity & liabilities | ||||||
| Share capital | 2.28 | 2.28 | 1.68 | 1.50 | 1.50 | 0.67 |
| Reserves & surplus | 6.97 | 6.55 | 1.87 | 0.88 | 0.35 | 0.72 |
| Shareholders' funds (net worth) | 9.25 | 8.83 | 3.55 | 2.38 | 1.85 | 1.39 |
| Secured loans | 0.36 | 0.00 | 0.53 | 0.59 | 0.64 | 0.48 |
| Unsecured loans | 0.00 | 0.00 | 0.34 | 0.44 | 0.25 | 0.06 |
| Total debt | 0.36 | 0.00 | 0.87 | 1.03 | 0.89 | 0.54 |
| Total liabilities | 9.86 | 9.03 | 4.61 | 5.02 | 2.85 | 2.02 |
| Assets | ||||||
| Gross block | 5.90 | 5.33 | 4.47 | 3.65 | 3.52 | 2.45 |
| Net block | 2.18 | 2.12 | 1.71 | 1.33 | 1.65 | 0.84 |
| Capital work in progress | 0.99 | 1.01 | 0.94 | 0.56 | 0.41 | 0.08 |
| Investments | 0.08 | 0.07 | 0.07 | 2.02 | 0.14 | 0.09 |
| Inventories | 0.73 | 0.53 | 0.28 | 0.14 | 0.16 | 0.09 |
| Sundry debtors | 1.85 | 1.54 | 0.60 | 0.49 | 0.36 | 0.56 |
| Cash & bank balances | 2.06 | 3.07 | 0.70 | 0.78 | 0.10 | 0.32 |
| Loans & advances | 2.72 | 2.32 | 1.12 | 0.55 | 0.76 | 0.66 |
| Total current assets | 7.36 | 7.46 | 2.70 | 1.96 | 1.38 | 1.63 |
| Total current liabilities | 1.05 | 1.81 | 1.00 | 1.01 | 0.83 | 0.71 |
| Net working capital | 6.31 | 5.65 | 1.70 | 0.95 | 0.55 | 0.92 |
| Total assets | 9.86 | 9.03 | 4.61 | 5.02 | 2.85 | 2.02 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|---|
| Opening cash | 3.07 | 0.70 | 0.78 | 0.10 | 0.32 | 0.28 |
| Net cash from operating activities | (0.90) | (0.88) | (1.28) | 1.25 | 0.96 | 0.38 |
| Net cash from investing activities | (0.44) | (0.73) | 0.75 | (0.65) | (1.47) | 0.54 |
| Net cash from financing activities | 0.33 | 3.98 | 0.45 | 0.09 | 0.29 | (0.88) |
| Net change in cash | (1.01) | 2.37 | (0.08) | 0.68 | (0.22) | 0.04 |
| Closing cash | 2.06 | 3.07 | 0.70 | 0.78 | 0.10 | 0.32 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|---|
| Growth | ||||||
| Sales growth | +15.2% | +28.6% | +0.8% | -0.5% | +40.2% | - |
| EBITDA growth | +22.0% | -18.0% | -26.5% | +28.3% | +27.7% | - |
| PBT growth | +13.0% | +5.9% | -40.7% | +24.6% | +27.8% | +9997.0% |
| Net income growth | +48.3% | -21.6% | -39.3% | +22.0% | +35.1% | - |
| Revenue CAGR (3Y) | +14.3% | +8.9% | +12.0% | - | - | - |
| EBITDA CAGR (3Y) | -9.7% | -8.2% | +6.4% | - | - | - |
| Profitability & leverage | ||||||
| Net income margin | +4.5% | +4.6% | +5.9% | +9.6% | +7.8% | +8.8% |
| Return on capital employed | +7.1% | +7.9% | +12.3% | +23.6% | +31.2% | +30.7% |
| Return on net worth | +4.7% | +4.9% | +12.5% | +28.8% | +31.5% | +28.8% |
| Debt / equity | 0.02 | 0.07 | 0.32 | 0.45 | 0.44 | 0.38 |
| Long-term debt / equity | 0.02 | 0.02 | 0.09 | 0.15 | 0.26 | 0.34 |
| Interest cover | 14.29 | 16.22 | 16.07 | 7.69 | 8.82 | 13.79 |
| Efficiency & per share | ||||||
| Fixed asset turnover | 1.69 | 1.68 | 1.58 | 1.77 | 2.14 | 1.86 |
| Inventory turnover | 15.05 | 20.32 | 30.48 | 42.33 | 51.04 | 50.56 |
| Debtors turnover | 5.59 | 7.69 | 11.74 | 14.94 | 13.87 | 8.13 |
| EPS (₹) | 1.85 | 1.73 | 2.21 | 4.09 | 3.42 | 6.04 |
| Dividend per share (₹) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Book value per share (₹) | 40.54 | 38.69 | 21.12 | 15.87 | 12.32 | 20.86 |
Similar companies to Clinitech Laboratory
Clinitech Laboratory has 3 listed similar companies in our database, 3 of them funded. They include Dr Lal PathLabs, Redcliffe Labs and Sterling Accuris Diagnostics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| lalpathlabs.com | 1949 | Gurugram, India | $13.9M | 8,279 | Chain of pathology and radiology labs | |
| redcliffelabs.com | 2018 | Noida, India | $116.42M | 2,104 | Home-based diagnostic tests are booked via an online platform. | |
| sterlingaccuris.com | 2015 | Ahmedabad, India | $41.69M | 1,229 | Pathology diagnostic services are offered via a chain of labs. |
Detailed similar companies of Clinitech Laboratory
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Diagnostics Laboratories
3 companies that operate in the same segment as Clinitech Laboratory (Diagnostics Laboratories) in India, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Diagnostic testing centers for pathology and health screenings are operated. | 1996 | Mumbai, Maharashtra, India | USD 63.59 M | USD 90.17 M | 1,979 | |
Chain of pathology and radiology labs | 1949 | Gurugram, Haryana, India | USD 13.9 M | USD 294.49 M | 5,310 | |
Home-based diagnostic tests are booked via an online platform. | 2018 | Noida, Uttar Pradesh, India | USD 116.42 M | USD 52.45 M | 2,334 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Clinitech Laboratory
Complete news archive for Clinitech Laboratory
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Clinitech Laboratory
Clinitech Laboratory was founded in 1990.
Clinitech Laboratory is headquartered in Mumbai, India. It is registered at Mumbai, Maharashtra, India.
Jagdish Nayak is the CEO of Clinitech Laboratory, as recorded in our data.
The primary company behind Clinitech Laboratory, Clinitech Laboratory Limited, reported revenue of ₹9.68 Cr for FY 2026, up 15% year on year.
Clinitech Laboratory was founded in 1990 and functions as a chain of pathology labs based in Mumbai, India. Diagnostic services in pathology are delivered across multiple locations. Operations focus on medical testing and analysis for healthcare needs. Leadership is provided by CEO Jagdish Nayak. The company serves the healthcare sector within the Indian market.
Clinitech Laboratory's top competitors include Dr Lal PathLabs, Redcliffe Labs and Sterling Accuris Diagnostics.
Yes, Clinitech Laboratory is publicly traded on BSE under the ticker symbol CTLLAB.
Clinitech Laboratory is associated with 2 legal entities: Clinitech Laboratory Limited, Ctl Wellnz Llp.
The legal entities of Clinitech Laboratory currently have 9 directors, including Jagdish Umakant Nayak, Ashutosh Jagdish Nayak, Kripananda Chidambaram and others.
